Research progress of m6A methylation modification in regulating tumor immunity

doi:10.3969/j.issn.1674-8115.2024.01.016

Abstract

Abstract:

N⁶-methyladenosine (m⁶A) is the most prevalent modification that regulates gene expression in eukaryotes. It regulates splicing, degradation, stability, and translation of RNA. Numerous studies have demonstrated the close association between m⁶A methylation and tumor development, highlighting its crucial role in regulating tumor immune response. The m⁶A modification actively participates in governing immune cell differentiation and maturation as well as modulating anti-tumor immune responses. Within the tumor microenvironment, m⁶A modification can also impact the recruitment, activation, and polarization of immune cells, thereby either promoting or inhibiting tumor cell proliferation and metastasis. Consequently, it plays a pivotal role in reshaping the tumor immune microenvironment. In recent years, immunotherapy for tumors has been increasingly applied to clinical practice with notable success achieved through approaches such as immune checkpoint inhibitor therapy and adoptive cell immunotherapy. Targeting m⁶A modifications to interfere with the immune system, such as targeting dysregulated m⁶A regulators through small molecule inhibitors and inducing immune cell reprogramming, can improve anti-tumor immune response and strengthen immune cells′ ability to recognize and kill tumor cells. The m⁶A modification represents a novel avenue for potential clinical application within tumor immunotherapy. This review provides a comprehensive summary of the regulatory impact of m⁶A methylation modification on immune cells in the context of cancer, while also delving into novel targets for tumor immunotherapy.

Key words: m⁶A methylation, tumor immunity, immunotherapy

CLC Number:

R730.51

ZHOU Haixia, ZHANG Jing. Research progress of m⁶A methylation modification in regulating tumor immunity[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(1): 137-144.

Figures/Tables 3

TrendMD

References 58

1	YI Y C, CHEN X Y, ZHANG J, et al. Novel insights into the interplay between m⁶A modification and noncoding RNAs in cancer[J]. Mol Cancer, 2020, 19(1): 121.
2	SHULMAN Z, STERN-GINOSSAR N. The RNA modification N⁶-methyladenosine as a novel regulator of the immune system[J]. Nat Immunol, 2020, 21(5): 501-512.
3	WANG X, LU Z K, GOMEZ A, et al. N⁶-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014, 505(7481): 117-120.
4	LI A, CHEN Y S, PING X L, et al. Cytoplasmic m⁶A reader YTHDF3 promotes mRNA translation[J]. Cell Res, 2017, 27(3): 444-447.
5	ROUNDTREE I A, EVANS M E, PAN T, et al. Dynamic RNA modifications in gene expression regulation[J]. Cell, 2017, 169(7): 1187-1200.
6	DENG L J, DENG W Q, FAN S R, et al. m⁶A modification: recent advances, anticancer targeted drug discovery and beyond[J]. Mol Cancer, 2022, 21(1): 52.
7	JIA G F, FU Y, ZHAO X, et al. N⁶-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011, 7(12): 885-887.
8	ZHENG G Q, DAHL J A, NIU Y M, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell, 2013, 49(1): 18-29.
9	MORANTE-PALACIOS O, FONDELLI F, BALLESTAR E, et al. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases[J]. Trends Immunol, 2021, 42(1): 59-75.
10	DIAMOND M S, LIN J H, VONDERHEIDE R H. Site-dependent immune escape due to impaired dendritic cell cross-priming[J]. Cancer Immunol Res, 2021, 9(8): 877-890.
11	WANG H M, HU X, HUANG M Y, et al. Mettl3-mediated mRNA m⁶A methylation promotes dendritic cell activation[J]. Nat Commun, 2019, 10(1): 1898.
12	LIU J, ZHANG X M, CHEN K, et al. CCR7 chemokine receptor-inducible lnc-Dpf3 restrains dendritic cell migration by inhibiting HIF-1α-mediated glycolysis[J]. Immunity, 2019, 50(3): 600-615.e15.
13	HAN D L, LIU J, CHEN C Y, et al. Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells[J]. Nature, 2019, 566(7743): 270-274.
14	WU S Y, FU T, JIANG Y Z, et al. Natural killer cells in cancer biology and therapy[J]. Mol Cancer, 2020, 19(1): 120.
15	SONG H, SONG J X, CHENG M, et al. METTL3-mediated m⁶A RNA methylation promotes the anti-tumour immunity of natural killer cells[J]. Nat Commun, 2021, 12(1): 5522.
16	MA S B, YAN J Z, BARR T, et al. The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity[J]. J Exp Med, 2021, 218(8): e20210279.
17	LEWIS C E, POLLARD J W. Distinct role of macrophages in different tumor microenvironments[J]. Cancer Res, 2006, 66(2): 605-612.
18	CAUX C, RAMOS R N, PRENDERGAST G C, et al. A milestone review on how macrophages affect tumor growth[J]. Cancer Res, 2016, 76(22): 6439-6442.
19	PITTET M J, MICHIELIN O, MIGLIORINI D. Clinical relevance of tumour-associated macrophages[J]. Nat Rev Clin Oncol, 2022, 19(6): 402-421.
20	LIU Y H, LIU Z J, TANG H, et al. The N ⁶-methyladenosine (m⁶A)-forming enzyme METTL3 facilitates M1 macrophage polarization through the methylation of STAT1 mRNA[J]. Am J Physiol Cell Physiol, 2019, 317(4): C762-C775.
21	YIN H L, ZHANG X, YANG P Y, et al. RNA m⁶A methylation orchestrates cancer growth and metastasis via macrophage reprogramming[J]. Nat Commun, 2021, 12(1): 1394.
22	MA S B, SUN B F, DUAN S Q, et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8⁺ T cells[J]. Nat Immunol, 2023, 24(2): 255-266.
23	OLINGY C E, DINH H Q, HEDRICK C C. Monocyte heterogeneity and functions in cancer[J]. J Leukoc Biol, 2019, 106(2): 309-322.
24	XIE J Y, HUANG Z J, JIANG P, et al. Elevated N6-methyladenosine RNA levels in peripheral blood immune cells: a novel predictive biomarker and therapeutic target for colorectal cancer[J]. Front Immunol, 2021, 12: 760747.
25	ZHANG X N, LI X, JIA H T, et al. The m⁶A methyltransferase METTL3 modifies PGC-1α mRNA promoting mitochondrial dysfunction and oxLDL-induced inflammation in monocytes[J]. J Biol Chem, 2021, 297(3): 101058.
26	JAILLON S, PONZETTA A, MITRI D D, et al. Neutrophil diversity and plasticity in tumour progression and therapy[J]. Nat Rev Cancer, 2020, 20(9): 485-503.
27	OU B C, LIU Y, YANG X W, et al. C5aR1-positive neutrophils promote breast cancer glycolysis through WTAP-dependent m6A methylation of ENO1[J]. Cell Death Dis, 2021, 12(8): 737.
28	OU B C, LIU Y, GAO Z X, et al. Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m⁶A demethylation[J]. Cell Death Dis, 2022, 13(10): 905.
29	VEGLIA F, SANSEVIERO E, GABRILOVICH D I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498.
30	CHEN H R, PAN Y S, ZHOU Q M, et al. METTL3 inhibits antitumor immunity by targeting m⁶A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer[J]. Gastroenterology, 2022, 163(4): 891-907.
31	WANG L N, ZHU L F, LIANG C, et al. Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis[J]. J Hepatol, 2023, 79(5): 1185-1200.
32	SILVA-SANTOS B, MENSURADO S, COFFELT S B. γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer[J]. Nat Rev Cancer, 2019, 19(7): 392-404.
33	DING C B, XU H, YU Z B, et al. RNA m⁶A demethylase ALKBH5 regulates the development of γδ T cells[J]. Proc Natl Acad Sci U S A, 2022, 119(33): e2203318119.
34	XIAO Z Q, WANG S S, TIAN Y X, et al. METTL3-mediated m⁶A methylation orchestrates mRNA stability and dsRNA contents to equilibrate γδ T1 and γδ T17 cells[J]. Cell Rep, 2023, 42(7): 112684.
35	LICHTERMAN J N, REDDY S M. Mast cells: a new frontier for cancer immunotherapy[J]. Cells, 2021, 10(6): 1270.
36	GUO W, TAN F W, HUAI Q L, et al. Comprehensive analysis of PD-L1 expression, immune infiltrates, and m⁶A RNA methylation regulators in esophageal squamous cell carcinoma[J]. Front Immunol, 2021, 12: 669750.
37	XU Z Y, CHEN Q L, SHU L L, et al. Expression profiles of m⁶A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer[J]. Front Oncol, 2022, 12: 970367.
38	LEONI C, BATACLAN M, ITO-KUREHA T, et al. The mRNA methyltransferase Mettl3 modulates cytokine mRNA stability and limits functional responses in mast cells[J]. Nat Commun, 2023, 14(1): 3862.
39	WALSH S R, SIMOVIC B, CHEN L, et al. Endogenous T cells prevent tumor immune escape following adoptive T cell therapy[J]. J Clin Invest, 2019, 129(12): 5400-5410.
40	SI J W, SHI X J, SUN S H, et al. Hematopoietic progenitor kinase1 (HPK₁) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies[J]. Cancer Cell, 2020, 38(4): 551-566.e11.
41	BORST J, AHRENDS T, BĄBAŁA N, et al. CD4⁺ T cell help in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2018, 18(10): 635-647.
42	LI H B, TONG J Y, ZHU S, et al. m⁶A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways[J]. Nature, 2017, 548(7667): 338-342.
43	ZHOU J, ZHANG X L, HU J J, et al. m⁶A demethylase ALKBH5 controls CD4⁺ T cell pathogenicity and promotes autoimmunity[J]. Sci Adv, 2021, 7(25): eabg0470.
44	LU T X, ZHENG Z, ZHANG L D, et al. A new model of spontaneous colitis in mice induced by deletion of an RNA m⁶A methyltransferase component METTL14 in T cells[J]. Cell Mol Gastroenterol Hepatol, 2020, 10(4): 747-761.
45	TONG J Y, CAO G C, ZHANG T, et al. m⁶A mRNA methylation sustains treg suppressive functions[J]. Cell Res, 2018, 28(2): 253-256.
46	DONG L H, CHEN C Y, ZHANG Y W, et al. The loss of RNA N⁶-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8⁺ Tcell dysfunction and tumor growth[J]. Cancer Cell, 2021, 39(7): 945-957.e10.
47	TSUCHIYA K, YOSHIMURA K, INOUE Y, et al. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer[J]. Oncoimmunology, 2021, 10(1): 1962656.
48	LIU Z C, WANG T T, SHE Y L, et al. N⁶-methyladenosine-modified circIGF2BP3 inhibits CD8⁺ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer[J]. Mol Cancer, 2021, 20(1): 105.
49	LIU Y, LIANG G H, XU H J, et al. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance[J]. Cell Metab, 2021, 33(6): 1221-1233.e11.
50	LAUMONT C M, NELSON B H. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity[J]. Cancer Cell, 2023, 41(3): 466-489.
51	ZHENG Z, ZHANG L D, CUI X L, et al. Control of early B cell development by the RNA N⁶-methyladenosine methylation[J]. Cell Rep, 2020, 31(13): 107819.
52	HUANG H J, ZHANG G P, RUAN G X, et al. Mettl14-mediated m6A modification is essential for germinal center B cell response[J]. J Immunol, 2022, 208(8): 1924-1936.
53	XU A S, ZHANG J S, ZUO L P, et al. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF₁ in an m⁶A-YTHDF2-dependent manner[J]. Mol Ther, 2022, 30(3): 1104-1118.
54	WANG L L, HUI H, AGRAWAL K, et al. m⁶ A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy[J]. EMBO J, 2020, 39(20): e104514.
55	BAO Y, ZHAI J N, CHEN H R, et al. Targeting m⁶A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer[J]. Gut, 2023, 72(8): 1497-1509.
56	HUANG Y, SU R, SHENG Y, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia[J]. Cancer Cell, 2019, 35(4): 677-691.e10.
57	YANKOVA E, BLACKABY W, ALBERTELLA M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature, 2021, 593(7860): 597-601.
58	ZHANG B, WU Q, LI B, et al. m⁶A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer[J]. Mol Cancer, 2020, 19(1): 53.

Immune cell	m⁶A regulator	Type	Related factor	Function	Reference
DC	METTL3	Writer	CD40, CD80 and Tirap	Positively correlates with DC maturation and function in promoting T-cell activation	[11]
	YTHDF1	Reader	Lysosomal proteases	Negatively correlates with cross-presentation of engulfed tumour neoantigens	[13]
	YTHDF2	Reader	lnc-Dpf3	Positively correlates with DC migration	[12]
NK	METTL3	Writer	SHP-2	Positively correlates antitumor immunity of NK cells	[15]
NK	YTHDF2	Reader	Tardb	Positively correlates with NK cell antitumor activity as well as NK cell homeostasis and maturation	[16]
TAM	METTL3	Writer	STAT1, STAT3	Positively correlates with M1 macrophage polarization	[20-21]
TAM	YTHDF2	Reader	STAT1	Negatively correlates with macrophage reprogramming and antitumor immunity	[22]
Monocyte	METTL3	Writer	PGC-1α	Positively correlates with monocyte differentiation into different types of macrophages	[25]
Neutrophil	WTAP	Writer	ENO1	Positively correlates with tumor glycolysis mediated by C5aR1-positive neutrophils	[27]
Neutrophil	FTO	Eraser	ZEB1	Positively correlates with senescent neutrophils-mediated chemoresistance in breast cancer	[28]
MDSC	METTL3	Writer	BHLHE41	Positively correlates with MDSC migration	[30]
MDSC	YTHDF1	Reader	EZH2	Positively correlates with MDSC recruitment and activation	[31]
γδ T cell	METTL3	Writer	STAT1	Positively correlates with equilibrate γδ T1 and γδ T17 cells	[34]
γδ T cell	ALKBH5	Eraser	Jagged1/Notch2	Negatively correlates with proliferation and differentiation of γδ T cell precursors	[33]
Mast cell	METTL3	Writer	IL-13	Negatively correlates with inflammatory responses of mast cells	[38]

Immune cell	m⁶A regulator	Type	Related factor	Function	Reference
DC	METTL3	Writer	CD40, CD80 and Tirap	Positively correlates with DC maturation and function in promoting T-cell activation	[11]
	YTHDF1	Reader	Lysosomal proteases	Negatively correlates with cross-presentation of engulfed tumour neoantigens	[13]
	YTHDF2	Reader	lnc-Dpf3	Positively correlates with DC migration	[12]
NK	METTL3	Writer	SHP-2	Positively correlates antitumor immunity of NK cells	[15]
NK	YTHDF2	Reader	Tardb	Positively correlates with NK cell antitumor activity as well as NK cell homeostasis and maturation	[16]
TAM	METTL3	Writer	STAT1, STAT3	Positively correlates with M1 macrophage polarization	[20-21]
TAM	YTHDF2	Reader	STAT1	Negatively correlates with macrophage reprogramming and antitumor immunity	[22]
Monocyte	METTL3	Writer	PGC-1α	Positively correlates with monocyte differentiation into different types of macrophages	[25]
Neutrophil	WTAP	Writer	ENO1	Positively correlates with tumor glycolysis mediated by C5aR1-positive neutrophils	[27]
Neutrophil	FTO	Eraser	ZEB1	Positively correlates with senescent neutrophils-mediated chemoresistance in breast cancer	[28]
MDSC	METTL3	Writer	BHLHE41	Positively correlates with MDSC migration	[30]
MDSC	YTHDF1	Reader	EZH2	Positively correlates with MDSC recruitment and activation	[31]
γδ T cell	METTL3	Writer	STAT1	Positively correlates with equilibrate γδ T1 and γδ T17 cells	[34]
γδ T cell	ALKBH5	Eraser	Jagged1/Notch2	Negatively correlates with proliferation and differentiation of γδ T cell precursors	[33]
Mast cell	METTL3	Writer	IL-13	Negatively correlates with inflammatory responses of mast cells	[38]

Immune cell	m⁶A regulator	Type	Related factor	Function	Reference
CD4⁺T cell	METTL3	Writer	SOCS	Positively correlates with proliferation and differentiation of T cells	[42]
CD4⁺T cell	ALKBH5	Eraser	IFN-γ, CXCL2	Positively correlates with Th1 cell activation	[43]
Treg cell	METTL3	Writer	SOCS	Positively correlates with sustaining Treg suppressive functions	[45]
Treg cell	METTL14	Writer	RORγt	Positively correlates with Tregs differentiation	[44]
CD8⁺T cell	METTL3	Writer	circIGF2BP3	Negatively correlates with CD8⁺T cell responses and facilitates tumor immune	[48]
	METTL14	Writer	Ebi3	Negatively correlates with dysfunctional CD8⁺T cell levels in patients with colorectal cancer	[46]
	YTHDF1/2	Reader	unkown	Positively correlates with tumor-infiltrating lymphocytes, including CD8⁺T cells	[47]
	FTO	Eraser	c-Jun, JunB, and C/EBPβ	Positively correlates with glycolytic metabolism of tumor cells; negatively correlates with CD8⁺T cell responses	[49]
B cell	METTL14	Writer	Lax1, Tipe2	Positively correlates with B cell maturation	[52]
B cell	FTO	Eraser	HSF1	Positively correlates with tumor-promoting and pro-metastatic in multiple myeloma	[53]

Immune cell	m⁶A regulator	Type	Related factor	Function	Reference
CD4⁺T cell	METTL3	Writer	SOCS	Positively correlates with proliferation and differentiation of T cells	[42]
CD4⁺T cell	ALKBH5	Eraser	IFN-γ, CXCL2	Positively correlates with Th1 cell activation	[43]
Treg cell	METTL3	Writer	SOCS	Positively correlates with sustaining Treg suppressive functions	[45]
Treg cell	METTL14	Writer	RORγt	Positively correlates with Tregs differentiation	[44]
CD8⁺T cell	METTL3	Writer	circIGF2BP3	Negatively correlates with CD8⁺T cell responses and facilitates tumor immune	[48]
	METTL14	Writer	Ebi3	Negatively correlates with dysfunctional CD8⁺T cell levels in patients with colorectal cancer	[46]
	YTHDF1/2	Reader	unkown	Positively correlates with tumor-infiltrating lymphocytes, including CD8⁺T cells	[47]
	FTO	Eraser	c-Jun, JunB, and C/EBPβ	Positively correlates with glycolytic metabolism of tumor cells; negatively correlates with CD8⁺T cell responses	[49]
B cell	METTL14	Writer	Lax1, Tipe2	Positively correlates with B cell maturation	[52]
B cell	FTO	Eraser	HSF1	Positively correlates with tumor-promoting and pro-metastatic in multiple myeloma	[53]

[1]	MENG Jing, XIE Yuting, ZUO Jiaxin, XIONG Ping. Nanoengineered T cell system for the in vitro treatment of oral squamous cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 866-873.
[2]	CHEN Zixuan, LIU Min. Research progress on immune cell therapy in renal cell carcinoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(7): 916-925.
[3]	ZHANG Difan, WANG Minghui, ZHAO Jie, WAN Jiangbo, HUANG Fang, HAO Siguo. Anti-leukemia effect of B7 gene-modified leukemia cell-derived exosomes [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 129-137.
[4]	TANG Junqian, LI Benshang. Advances in the treatment of pediatric B-cell acute lymphoblastic leukemia with high-risk cytogenetics [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(10): 1390-1399.
[5]	HE Rui, YAN Kepeng, WANG Jing. Targeting folate cycle enhances effects of cancer immunotherapy by modulating myeloid-derived suppressor cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(8): 1011-1022.
[6]	HU Fei, CAI Xiaohan, CHENG Rui, JI Shiyu, MIAO Jiaxin, ZHU Yan, FAN Guangjian. Progress in translational research on immunotherapy for osteosarcoma [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024, 44(7): 814-821.
[7]	ZHOU Xiaowen, LI Qian, ZHANG Zhe, SHEN Jianfeng, FAN Xianqun. RBX1 regulates uveal melanoma immune-related genes via STAT1 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(6): 709-717.
[8]	ZHAO Zhuoming, LIU Zhenhao, LU Manman, ZHANG Yu, XU Linfeng, XIE Lu. Analysis of tumor-related features of non-small cell lung cancer based on TCR repertoire workflow [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(12): 1520-1528.
[9]	LIU Junjun, LU Sumei, ZHANG Bingyang, LI Yongqing, MA Wanshan. Analysis of m⁶A methylation expression profiles in liver tissue of high-fat diet-induced mouse models of NAFLD [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(10): 1227-1235.
[10]	LU Yu, WANG Hao, BA Qian. Role of gut microbiota in hepatocellular carcinoma: cancer occurrence, progresses and treatments [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(7): 939-944.
[11]	Xu-xin-yi LING, Yao ZHANG, Hua ZHONG. Research progress in screening non-small cell lung cancer patients who will benefit from immunotherapy [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1114-1119.
[12]	Jing-wei LI, Li-wen WANG, Ling-xi JIANG, Qian ZHAN, Hao CHEN, Bai-yong SHEN. Review of immunosuppressive tumor microenvironment of pancreatic cancer [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(8): 1103-1108.
[13]	Paerhati NADINA, Yan YAN, Qian-ji CHE, Jing LUO, Xin-nan LIU, Bin LI. Application and prospect of chimeric antigen receptor-modified T cell therapy for glioblastoma [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 982-986.
[14]	Yun-fang MA, Li-na PAN, Zhen LI, Bei-li GAO, Jia-an HU, Zhi-hong XU. Exploratory study on downregulation of PD-L1 in KRAS G12V-mutant non-small cell lung cancer cells by selumetinib [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(6): 741-748.
[15]	Ling-ling LI, Qian LI, Ming-yu LI, Zheng LIU, Qian-cheng SHEN. Analysis of tumor immune-related differentially expressed genes in adults and children with acute myeloid leukemia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 579-587.

Research progress of m⁶A methylation modification in regulating tumor immunity

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

TrendMD

References 58

Related Articles 15

Recommended Articles

Metrics

Comments